DD (E.I. du Pont)

1= Strong Buy 5=Strong Sell

Summary:

This biotech company hit a 52-week low in mid July as the markets were declining significantly.  The stock is up 2.7% this year but is up 5.6% in the past month.  We see the only reason for this decline is a negative sentiment in the stock market making this stock an appealing buy.  With a dividend yield of 3.62% and a PEG of 2.02 we see this share price as an opportunity to buy.  With a P/E ratio below the industry average and 67% institutional ownership we give this stock a rating of a buy.  The reason we have not given it a strong buy rating is the recent price spike and the fact that the shares have gotten closer to their 52-week high.

Fiscal Frenzy Gain:-5.01%

Fiscal Frenzy Biggest Gains:

Dow Jones Industrial: -11.78%

Fiscal Frenzy Biggest Losses:

Top Stock Ratings:

CVX: Rating 1

CAT: Rating 1

MMM: Rating 1

For all our other stocks, just search a stock in the search box.